Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2022 | Going beyond BCMA-targeting agents in myeloma: GPRC5D and FcRH5-targeting therapies

Hans Lee • 25 Oct 2022
SOHO Italy 2022
Multiple Myeloma Antibodies BiTEs Cevostamab Talquetamab

In this video, Hans Lee, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the importance of GPRC5D and FcRH5-targeting therapies in multiple myeloma, highlighting agents such as talquetamab and cevostamab. Dr Lee comments on the efficacy of these agents observed in clinical trials, and further discusses their place in the myeloma treatment armamentarium. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Hans Lee

2:57
LINKER-MM1: promising safety and efficacy of linvoseltamab in R/R multiple myeloma
Hans Lee • 10 Dec 2023
5:14
LINKER-MM1: linvoseltamab in patients with R/R multiple myeloma
Hans Lee • 4 Jun 2023
2:12
Risk of infection and mitigation strategies in patients with myeloma treated with bispecifics
Hans Lee • 4 Jun 2023
1:47
Role of BCMA-targeting ADCs in the management of myeloma
Hans Lee • 4 Jun 2023

Related Videos

4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals